Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review

doi:10.4292/wjgpt.120122

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(2)

(0)

(8)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Pharmacol Ther. Sep 5, 2026; 17(3): 120122
Published online Sep 5, 2026. doi: 10.4292/wjgpt.120122

Full Size Figure Download Figure

Figure 2 The antifibrotic effects of nor-ursodeoxycholic acid are attributable to its suppressive effects on the transforming growth factor-β-small mothers against decapentaplegic pathway. Suppressing hepatic stellate cell, it inhibits collagen synthesis and attenuates fibrosis. UDCA: Ursodeoxycholic acid; TGF: Transforming growth factor; SMAD: Small mothers against decapentaplegic; SMA: Smooth muscle actin; ECM: Extracellular matrix.

Citation: Malakar S, Sood N, Giri S, Samanta A. Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review. World J Gastrointest Pharmacol Ther 2026; 17(3): 120122
URL: https://www.wjgnet.com/2150-5349/full/v17/i3/120122.htm
DOI: https://dx.doi.org/10.4292/wjgpt.120122

Malakar S, Sood N, Giri S, Samanta A. Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review. World J Gastrointest Pharmacol Ther 2026; 17(3): 120122 [DOI: 10.4292/wjgpt.120122]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.